Alkermes (Alkermes) Total Revenue Growth Rate (Future 3Y To 5Y Est) : -2.30 (As of Apr. 27, 2024)

View and export this data going back to 1991. Start your Free Trial

What is Alkermes Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Alkermes's Total Revenue Growth Rate (Future 3Y To 5Y Est) is -2.30.

Competitive Comparison of Alkermes's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alkermes's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Alkermes's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.

Alkermes (NAS:ALKS) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Alkermes Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Alkermes's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Alkermes (Alkermes) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Comparable Companies

Traded in Other Exchanges

8AK:Germany

Address

1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6

Website

https://www.alkermes.com

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Executives

Cato T Laurencin	director	C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols	officer: SVP, Chief Commercial Officer	852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski	director	2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr.	director	ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright	director	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine	officer: SVP, Corp Dev., Alkermes, Inc.	88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops	director, officer: Director and CEO, Alkermes plc	10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke	officer: President, Alkermes plc	TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson	officer: EVP, Chief Operating Officer	852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md	director	37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson	officer: SVP, Med Dev/Med Affairs, CMO	852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown	officer: VP, Finance & CAO	14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon	director	IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin	officer: SVP, CLO, Alkermes, Inc.	852 WINTER STREET, WALTHAM MA 02451